Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/19/2025

Risankizumab Efficacy and Safety

Approved Indications and Efficacy

  • The European Crohn's and Colitis Organisation (ECCO) guidelines provide strong recommendations for risankizumab in Crohn's disease based on high-quality evidence, recommending it for induction and maintenance therapy in moderate-to-severe Crohn's disease 1
  • The 2023 EULAR guidelines recognize risankizumab as one of the novel biological DMARDs targeting IL-23-p19 that has shown efficacy for the treatment of psoriatic arthritis 2

Positioning in Treatment Algorithms

  • For patients with both psoriatic arthritis and significant skin involvement, IL-23 inhibitors or IL-17 inhibitors are recommended over TNF inhibitors, according to the European League Against Rheumatism (EULAR) recommendations 3
  • The EULAR recommendations note that biologicals targeting IL-23-p19 (including risankizumab) appear encouraging, particularly for skin manifestations 3, 4

Safety Profile

  • Mild localized infections are a common adverse event associated with risankizumab treatment, as reported in the Annals of the Rheumatic Diseases 3